The Pink Elephant: MHT After Breast Cancer — A Review of the Data
Roughly 4 million breast cancer survivors are living in the United States, and that number grows every year. Most of them will outlive their disease. A significant portion of them will also spend years — sometimes decades — in estrogen deprivation, managing the menopausal consequences of treatment they needed to survive. And the majority of them cannot find a clinician prepared to have a real conversation about it.
That gap — between the scale of the problem and the clinical response to it — is what this MNDG session set out to address directly.
This is Part 1 of a two-part Monday Night Discussion Group series. The February 11, 2025, session was led by Dr. Corinne Menn and Dr. Amy Comander, MD, DipABLM, with Dr. Maryam Lustberg and Dr. Mary Jane Minkin joining as discussants. Part 2 moves into clinical cases, with Dr. Lustberg and Dr. Minkin leading.
The Menopause Management Vacuum — And Why It Hits Survivors Hardest
Dr. Menn opened with the structural problem: survey data showing that fewer than 1 in 10 ob-gyn, internal medicine, and family practice residents felt prepared to provide menopause care upon completion of training. That's the baseline — before factoring in that no serious curriculum in menopause management exists for oncologists, breast surgeons, or the other specialists who are often the primary clinical contact for breast cancer patients post-treatment.
The result is a survivorship care system that acknowledges the problem without resolving it. Women who've completed breast cancer treatment face profound estrogen deprivation — vasomotor symptoms, GSM, sleep disruption, metabolic changes, bone loss, cognitive effects — and find that the clinicians best positioned to treat the cancer are often not trained to address what the treatment left behind. The clinicians who are trained in menopause medicine frequently won't touch the conversation once breast cancer is in the chart.
Twenty percent of women diagnosed with breast cancer are under 50. Fifty thousand per year. That's not a niche population.
What the Data Actually Shows — And Why It's Been Misread
Dr. Menn walked through the full evidence timeline: roughly two decades of published studies on MHT in breast cancer survivors, the two landmark randomized controlled trials, and the long shadow of the WHI, which, she argued, distorted the interpretation of data that didn't actually point where clinicians have assumed it does.
The two pivotal RCTs — HABITS and the Stockholm trial — reached different conclusions, and Dr. Menn made the case that understanding why they differed matters as much as the headline findings. The HABITS trial, which reported an increased recurrence signal and was widely cited as the definitive answer, was terminated early, and Dr. Menn surfaced the distinction between why it was terminated and what the data at that point actually supported. The Stockholm trial, using a different hormonal regimen and with mandatory mammogram screening, reported no difference in breast cancer events at four or ten years.
One framing from the session is worth sitting with: the difference between the HABITS hormone therapy arm and the control arm comprised 22 patients. On the basis of that difference, MHT has been categorically withheld from millions of breast cancer survivors, many of whom were never told the conversation was possible.
Dr. Menn also addressed the Menopause Society's position statement directly — specifically the gap between what the statement actually says and the clinical shorthand that has calcified around it. The nuanced language in the position statement, she argued, is being collapsed into a blanket contraindication that the statement itself does not support.
Recurrence Risk — What Clinicians Need to Understand Before the Conversation Starts
Before any MHT discussion can happen, Dr. Menn argued, a clinician needs a working understanding of the patient's individual recurrence risk — and most non-oncologist clinicians don't have it. That includes distinguishing among the risk of local recurrence, the risk of a new primary, and the risk of late distant recurrence, which in ER-positive disease continues well beyond the 5-year mark that patients are often told represents safety.
Dr. Comander reinforced this from the oncology side, grounding it in breast cancer biology. She walked through the molecular subtypes — luminal A, luminal B, HER2-enriched, triple-negative — and what each means for how we think about estrogen sensitivity, recurrence timing, and the clinical logic of adjuvant endocrine therapy. The conversation about MHT cannot be the same conversation across all of these subtypes, and the session made clear that it often isn't differentiated at the point of care.
Dr. Comander also addressed the stakes of endocrine therapy adherence — and why they make the symptom management conversation unavoidable. Tamoxifen and aromatase inhibitors are doing real work. Patients who can't tolerate the side effects stop taking them. That clinical reality is part of what makes the blanket refusal to address MHT not just a quality-of-life issue, but potentially an oncologic one.
The Shared Decision Making Question — And a Parallel Worth Considering
One of the sharper moments in the session came when Dr. Menn drew a parallel between how the field approaches fertility preservation in young breast cancer survivors — where shared decision making is actively supported, even with imperfect data — and how it approaches menopause management in the same patients years later, where the conversation often doesn't happen at all.
The POSITIVE trial data on pregnancy after ER-positive breast cancer, she noted, shows the field's capacity to hold complexity when it values the outcome enough to study it.
"Patients are looking for partnership, not permission." — Corinne Menn, DO
The session did not conclude with a clinical protocol. It concluded with a framework: understand the patient's recurrence risk, understand the evidence and its limits, and engage in genuine shared decision making — documented, individualized, and collaborative with oncology. What Dr. Menn proposed is a practice posture, not a prescription. The recording is where the clinical substance lives.
Access the Full Recording
The full session — including Dr. Menn's complete literature review, Dr. Comander's molecular subtype framework, and the Q&A held for Part 2 — is available to HERmedicine members.
Frequently Asked Questions
Can breast cancer survivors use menopausal hormone therapy?
The evidence is more nuanced than clinical practice reflects. The two landmark RCTs — HABITS and the Stockholm trial — reached different conclusions, and neither definitively supports a blanket contraindication. The Menopause Society's position statement supports individualized shared decision-making rather than categorical refusal.
What did the HABITS trial actually show?
The HABITS trial was terminated early after reporting increased recurrences in the hormone therapy arm — a difference of 22 events between arms. Critics note the trial lacked statistical power at termination. The Stockholm trial, using a different regimen and mandatory mammography, reported no difference in breast cancer events at four or ten years.
What is the Menopause Society's position on MHT after breast cancer?
The Menopause Society's position statement does not issue a blanket contraindication to MHT for all breast cancer survivors. It supports individualized assessment weighing recurrence risk, symptom burden, and quality of life. The nuanced language in the statement is frequently collapsed into categorical guidance that the statement itself does not support.
How does breast cancer subtype affect MHT decision-making?
Molecular subtype significantly changes the risk calculus. ER-positive disease carries ongoing late recurrence risk well beyond five years and is estrogen-sensitive, making the MHT conversation more complex. Triple-negative disease has a different recurrence timing curve and distinct estrogen-sensitivity profile, which changes the clinical framework substantially.
About the Speakers
Corinne Menn, DO, MSCP
Corinne Menn, DO MSCP, is an OB-GYN and menopause-certified practitioner whose clinical work sits at the intersection of menopause medicine and breast cancer survivorship. A 23-year breast cancer survivor and BRCA2 carrier, she brings both clinical expertise and firsthand patient experience to a topic she has spent her career working to normalize. Dr. Menn provides telehealth consultations in menopause management and survivorship, serves on the advisory board of the Young Survival Coalition, and has developed CME programming specifically for clinicians navigating MHT decisions in breast cancer survivors.
Amy Comander, MD, DipABLM
Amy Comander, MD, DipABLM, is a breast oncologist at Mass General Cancer Center, where she serves as Director of Breast Oncology and Cancer Survivorship and Director of the Lifestyle Medicine Program. She is also the Medical Director of Mass General Cancer Center in Waltham, Massachusetts. Her clinical focus is whole-patient care across the breast cancer continuum, with particular attention to quality of life, survivorship, and evidence-based lifestyle medicine.
Maryam Lustberg, MD, MPH
Maryam Lustberg, MD, MPH, is Chief of Breast Oncology and Director of the Breast Center at Yale Cancer Center in New Haven, Connecticut. She serves as co-chair of symptom intervention research for Alliance Clinical Trials and is the immediate past president of MASCC, the international organization dedicated to advancing cancer supportive care. Her research focuses on the long-term sequelae of breast cancer treatment, including menopausal symptoms and survivorship outcomes. Dr. Lustberg presents in Part 2 of this series.
Mary Jane Minkin, MD
Mary Jane Minkin, MD, is a Clinical Professor of Obstetrics and Gynecology at Yale School of Medicine with nearly five decades in women's health. She is a recognized authority in menopause medicine and has been a practicing clinical voice across the full arc of the evidence — from the pre-WHI era through the present. Dr. Minkin presents in Part 2 of this series.
